98 related articles for article (PubMed ID: 34937858)
21. Response to: Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli
Bonelli M; Aletaha D
Ann Rheum Dis; 2021 Oct; 80(10):e167. PubMed ID: 34340982
[No Abstract] [Full Text] [Related]
22. Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli
Chung SH; Wener M; Bays AM; Rahbar H; Morishima C; Bryan AB; Fink SL; Cohen S; Mani NS; Chaudhary A; Gardner GC
Ann Rheum Dis; 2021 Oct; 80(10):e165. PubMed ID: 34340981
[No Abstract] [Full Text] [Related]
23. Response to: 'Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'' by Westhoff
Bonelli M; Aletaha D
Ann Rheum Dis; 2021 Oct; 80(10):e163. PubMed ID: 34272251
[No Abstract] [Full Text] [Related]
24. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
25. Post-SARS-CoV-2 vaccination specific antibody decrease - Thresholds for determining seroprevalence and seroneutralization differ.
Douxfils J; Gillot C; Mullier F; Favresse J
J Infect; 2021 Oct; 83(4):e4-e5. PubMed ID: 34407421
[No Abstract] [Full Text] [Related]
26. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
Benjamini O; Rokach L; Itchaki G; Braester A; Shvidel L; Goldschmidt N; Shapira S; Dally N; Avigdor A; Rahav G; Lustig Y; Ben David SS; Fineman R; Paz A; Bairey O; Polliack A; Levy I; Tadmor T
Haematologica; 2022 Mar; 107(3):625-634. PubMed ID: 34320789
[TBL] [Abstract][Full Text] [Related]
27. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients.
Piñana JL; Vázquez L; Martino R; de la Cámara R; Sureda A; Rodríguez-Veiga R; Garrido A; Sierra J; Ribera JM; Torrent A; Mateos MV; de la Rubia J; Tormo M; Díez-Campelo M; García-Gutiérrez V; Álvarez-Larrán A; Sancho JM; MartínGarcía-Sancho A; Yañez L; Pérez Simón JA; Barba P; Abrisqueta P; Álvarez-Twose I; Bonanad S; Lecumberri R; Ruiz-Camps I; Navarro D; Hernández-Rivas JÁ; Cedillo Á; García-Sanz R; Bosch F
Leuk Lymphoma; 2022 Mar; 63(3):538-550. PubMed ID: 34668835
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!
Guarino M; Cossiga V; Esposito I; Furno A; Morisco F
J Hepatol; 2022 Jan; 76(1):237-239. PubMed ID: 34358567
[No Abstract] [Full Text] [Related]
29. Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study.
Lesny P; Anderson M; Cloherty G; Stec M; Haase-Fielitz A; Haarhaus M; Santos C; Lucas C; Macario F; Haase M
J Nephrol; 2021 Aug; 34(4):975-983. PubMed ID: 34050904
[TBL] [Abstract][Full Text] [Related]
30. Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations.
Mado H; Adamczyk-Sowa M
J Neurol; 2021 Nov; 268(11):3998-3999. PubMed ID: 33864125
[No Abstract] [Full Text] [Related]
31. Importance of sample dilution in the evaluation of the antibody response after SARS-CoV-2 vaccination.
Favresse J; Douxfils J
J Infect; 2022 Jan; 84(1):94-118. PubMed ID: 34233149
[No Abstract] [Full Text] [Related]
32. Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response"by Bonelli
Benucci M; Damiani A; Infantino M; Manfredi M; Grossi V; Lari B; Li Gobbi F; Sarzi Puttini P
Ann Rheum Dis; 2021 Oct; 80(10):e166. PubMed ID: 34340979
[No Abstract] [Full Text] [Related]
33. Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia.
Ingelman-Sundberg HM; Blixt L; Wullimann D; Wu J; Gao Y; Healy K; Muschiol S; Bogdanovic G; Åberg M; Kjellander C; Grifoni A; Sette A; Aleman S; Chen P; Blennow O; Hansson L; Ljunggren HG; Chen MS; Buggert M; Österborg A
Haematologica; 2024 Feb; 109(2):646-651. PubMed ID: 37646668
[No Abstract] [Full Text] [Related]
34. [Expert recommendation for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients with HIV infection].
AIDS and Hepatitis C Professional Group, Chinese Society of Infectious Diseases
Zhonghua Nei Ke Za Zhi; 2021 Jul; 60(7):615-618. PubMed ID: 34619837
[TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los Angeles County, California, May 1-July 25, 2021.
Griffin JB; Haddix M; Danza P; Fisher R; Koo TH; Traub E; Gounder P; Jarashow C; Balter S
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1170-1176. PubMed ID: 34437525
[TBL] [Abstract][Full Text] [Related]
36. Adverse Events Following One Dose of mRNA COVID-19 Vaccination Among US Nursing Home Residents With and Without a Previous SARS-CoV-2 Infection.
Bardenheier BH; Gravenstein S; Blackman C; Gutman R; Sarkar IN; Feifer RA; White EM; McConeghy K; Nanda A; Bosco E; Mor V
J Am Med Dir Assoc; 2021 Nov; 22(11):2228-2232. PubMed ID: 34534492
[TBL] [Abstract][Full Text] [Related]
37. Seroconversion and dynamics of the anti-SARS-CoV-2 antibody response related to a hospital COVID-19 outbreak among pediatric oncology patients.
Mayanskiy N; Luchkina P; Fedorova N; Lebedin Y; Ponomareva N
Leukemia; 2021 Jun; 35(6):1820-1822. PubMed ID: 34007047
[No Abstract] [Full Text] [Related]
38. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
39. Ring vaccination of COVID-19 vaccines in medium- and high-risk areas of countries with low incidence of SARS-CoV-2 infection.
Xu W; Su S; Jiang S
Clin Transl Med; 2021 Feb; 11(2):e331. PubMed ID: 33634979
[No Abstract] [Full Text] [Related]
40. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.
Strengert M; Becker M; Ramos GM; Dulovic A; Gruber J; Juengling J; Lürken K; Beigel A; Wrenger E; Lonnemann G; Cossmann A; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Behrens GMN
EBioMedicine; 2021 Aug; 70():103524. PubMed ID: 34391096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
